GSK is on track to meet its 2024 outlook, fueled by robust sales and significant advancements in its research and development pipeline. The company reported strong growth in specialty medicines, which helped to counterbalance decreased vaccine sales. This performance underscores the resilience built into GSK’s portfolio.
R&D Momentum
GSK has reported eleven positive Phase III trials thus far in 2024. These results support the anticipated launches of five major new products in 2025. According to Emma Walmsley, Chief Executive Officer of GSK, the company is increasingly confident in its 2026 and 2031 outlooks.
Upcoming Product Launches
The planned launches for 2025 include:
- Blenrep: An antibody-drug conjugate targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma.
- Depemokimab: A long-acting monoclonal antibody in development for asthma.
- Nucala for COPD: An anti-IL-5 monoclonal antibody, already approved for asthma, seeking label expansion for chronic obstructive pulmonary disease (COPD).
- Gepotidacin: A novel antibacterial agent targeting bacterial topoisomerase, being developed to treat uncomplicated urinary tract infections (uUTIs) and gonorrhea.
- MenABCWY: A new vaccine designed to prevent meningitis caused by serogroups A, B, C, W, and Y of Neisseria meningitidis.
Financial Performance
The company's financial performance in Q3 2024 reflects the strategic shift towards specialty medicines and innovative therapies. This focus has not only driven growth but also mitigated the impact of fluctuating vaccine sales. GSK's resolution of the majority of Zantac litigation has further reduced uncertainty, allowing the company to concentrate on future growth opportunities.
